Malignant Urinary Tract Neoplasm — Trials

Malignant Urinary Tract Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,955 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 507
Recruiting: 271
Ph III recruiting: 36
Growth YoY: +23.2%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (246)

clinicaltrialsPublishedShowing 251–300 of 1,955 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05775471	Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer	recruiting	Phase 2	21	Jonsson Comprehensive Cancer CenterOTHER	1	Jul 16, 2026	clinicaltrials
NCT05843448	IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer	active not recruiting	Phase 1	6	University of California, DavisOTHER	1